Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with a median survival of 16.2-21.2 months post diagnosis (Stupp et al., N Engl J Med 352(10): 987-996, 2005). Because of its location, complete surgical resection is impossible; additionally because GBM is also resistant to chemo-therapeutic and radiotherapy approaches, development of novel therapies is urgently needed. In this chapter we describe the development of preclinical animal models and a conditionally cytotoxic and immune-stimulatory gene therapy strategy that successfully causes tumor regression in several rodent GBM models.
CITATION STYLE
Kamran, N., Candolfi, M., Baker, G. J., Ayala, M. M., Dzaman, M., Lowenstein, P. R., & Castro, M. G. (2016). Gene therapy for the treatment of neurological disorders: Central nervous system neoplasms. In Methods in Molecular Biology (Vol. 1382, pp. 467–482). Humana Press Inc. https://doi.org/10.1007/978-1-4939-3271-9_31
Mendeley helps you to discover research relevant for your work.